Scientists develop methods to convert non-embryonic stem cells into eye cells

NewsGuard 100/100 Score

In two separate studies, scientists have developed methods to convert non-embryonic stem cells into eye cells that could be used to restore sight. The research is being presented at the 2014 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Orlando.

In the first method, researchers converted cells taken from the front of a patient's eye into stem cells, which were then programmed to become nerve cells found in the back of the eye. The second study involved introducing stem cells to a single growth factor, which caused them to develop into tissue resembling the developing eye.

Both outcomes will play important roles toward generating sources of transplantable cells to replace damaged tissue in patients with impaired vision.

Abstract Title: Derivation, Characterization and Retinal Neural Induction of Human Tenon's -Derived iPS Cells

Presentation Start/End Time: Monday, May 5, 8:30 - 10:15am
Location: Exhibit/Poster Hall SA
Session Number: 218

Abstract Title: The formation of primitive ocular structures and stratified neural retina from human pluripotent stem cells

Presentation Start/End Time: Monday, May 5, 8:30 - 10:15am
Location: Exhibit/Poster Hall SA
Session Number: 218

The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include some 11,500 eye and vision researchers from over 70 countries. ARVO encourages and assists research, training, publication and knowledge-sharing in vision and ophthalmology.

All abstracts accepted for presentation at the ARVO Annual Meeting represent previously unpublished data and conclusions. This research may be proprietary or may have been submitted for journal publication. Embargo policy: Journalists must seek approval from the presenter(s) before reporting data from paper or poster presentations. Press releases or stories on information presented at the ARVO Annual Meeting may not be released or published until the conclusion of the presentation.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema